News Are biotech IPOs back in fashion? After a slow first quarter, biotech IPOs may finally start to come into vogue in the coming months as a series of companies announced plans to go public.
News Takeda to challenge GW Pharma with epilepsy deal Takeda makes epilepsy deal as GW prepares for US filing.
News Regeneron's three-monthly gMG drug Livsayis cleared by FDA Regeneron has joined the crowded gMG market with an siRNA-based therapy, Livsayis, that only needs to be dosed four times a year.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.